BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community - To The Moon

At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.

Close

BCTX BriaCell Therapeutics Corp.

Post-Mkt 09-02 16:57:11 EDT

3.57

-0.06

-1.65%

盘后3.56

-0.01-0.28%

16:18 EDT

High3.76	Low3.57	Vol94.48K
Open3.58	D1 Closing3.63	Amplitude5.23%
Mkt Cap31.06M	Tradable Cap28.06M	Total Shares8.70M
T/O341.50K	T/O Rate1.20%	Tradable Shares7.86M
P/B--	ROE--	EPS0.00
52wk High--	52wk Low--	P/E--
Dividend--	Div.Yield--	ROA--

Loading ...

{"stockData":{"symbol":"BCTX","market":"US","secType":"STK","nameCN":"BriaCell Therapeutics Corp.","latestPrice":3.57,"timestamp":1788379200000,"preClose":3.63,"halted":0,"volume":94479,"hourTrading":{"tag":"盘后","latestPrice":3.56,"preClose":3.57,"latestTime":"16:18 EDT","volume":358,"amount":1277.812801,"timestamp":1788380325135,"change":-0.01,"changeRate":-0.002801,"amplitude":0.002801},"delay":0,"changeRate":-0.016528925619834725,"floatShares":7859600,"shares":8699800,"eps":-9.659207,"marketStatus":"Post-Mkt","change":-0.06,"latestTime":"09-02 16:57:11 EDT","open":3.58,"high":3.76,"low":3.57,"amount":341495,"amplitude":0.052342,"askPrice":3.9,"askSize":13,"bidPrice":3.39,"bidSize":300,"shortable":3,"etf":0,"ttmEps":-9.659207,"tradingStatus":3,"nextMarketStatus":{"tag":"Closed","tradingStatus":0,"beginTime":1788393600000},"marketStatusCode":4,"adr":0,"listingDate":1614142800000,"exchange":"NASDAQ","adjPreClose":3.63,"preHourTrading":{"tag":"盘前","latestPrice":3.6,"preClose":3.63,"latestTime":"08:47 EDT","volume":491,"amount":1733.1208998000002,"timestamp":1788353220701,"change":-0.03,"changeRate":-0.008264,"amplitude":0.023609},"postHourTrading":{"tag":"盘后","latestPrice":3.56,"preClose":3.57,"latestTime":"16:18 EDT","volume":358,"amount":1277.812801,"timestamp":1788380325135,"change":-0.01,"changeRate":-0.002801,"amplitude":0.002801},"volumeRatio":0.36864,"impliedVol":0.6056,"impliedVolPercentile":0},"requestUrl":"/m/hq/s/BCTX/tweets","defaultTab":"tweets","newsList":[{"id":"2661275154","title":"BriaCell advances melanoma immunotherapy vaccine candidate Bria-MEL+","url":"https://stock-news.laohu8.com/highlight/detail?id=2661275154","media":"TIPRANKS","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2661275154?lang=en_us&edition=fundamental","pubTime":"2026-08-24 19:35","pubTimestamp":1787571306,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) announced that Bria-MEL+, its personalized whole cell melanoma immunotherapy vaccine candidate, has achieved a genetic engineering ...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-advances-melanoma-immunotherapy-vaccine-candidate-bria-mel-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-advances-melanoma-immunotherapy-vaccine-candidate-bria-mel-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","IDNA","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2657542258","title":"BriaCell Receives FDA Clearance to Initiate Bria-PROS+™ Clinical Study in Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2657542258","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2657542258?lang=en_us&edition=fundamental","pubTime":"2026-08-05 19:30","pubTimestamp":1785929400,"startTime":"0","endTime":"0","summary":"FDA clearance of Investigational New Drug (IND) application enables BriaCell to initiate Phase 1/2a clinical study of Bria-PROS+ in prostate cancerBria-PROS+ is BriaCell’s next generation personalized","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/08/05/3339216/0/en/BriaCell-Receives-FDA-Clearance-to-Initiate-Bria-PROS-Clinical-Study-in-Prostate-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4585","BK4588","LABU","BCTX","PROS","IND","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651441537","title":"Source Rock Royalties Declares Monthly Dividend and Grants New RSUs","url":"https://stock-news.laohu8.com/highlight/detail?id=2651441537","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651441537?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:51","pubTimestamp":1784202677,"startTime":"0","endTime":"0","summary":"An update from BriaCell Therapeutics ( ($TSE:BCT) ) is now available. Source Rock Royalties Ltd. has declared a monthly cash dividend of $0.0065 pe...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/source-rock-royalties-declares-monthly-dividend-and-grants-new-rsus?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/source-rock-royalties-declares-monthly-dividend-and-grants-new-rsus?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BCTX","BK4585","BK4139","VIG","BK4588"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651449646","title":"BriaCell Opens First Canadian Site – Sunnybrook – for Pivotal Phase 3 Trial in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2651449646","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651449646?lang=en_us&edition=fundamental","pubTime":"2026-07-16 19:30","pubTimestamp":1784201400,"startTime":"0","endTime":"0","summary":"Sunnybrook’s Odette Cancer Centre, a world-class cancer center in Toronto, Ontario, Canada, joins BriaCell’s pivotal Phase 3 clinical trial in metastatic breast cancerBriaCell Phase 3 trial featured i","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/16/3328357/0/en/BriaCell-Opens-First-Canadian-Site-Sunnybrook-for-Pivotal-Phase-3-Trial-in-Metastatic-Breast-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["CPI","BCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651785468","title":"BriaCell arranges scalable manufacturing with Fujifilm Biotechnologies","url":"https://stock-news.laohu8.com/highlight/detail?id=2651785468","media":"TIPRANKS","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651785468?lang=en_us&edition=fundamental","pubTime":"2026-07-15 20:10","pubTimestamp":1784117422,"startTime":"0","endTime":"0","summary":"BriaCell (BCTX) announced a manufacturing arrangement with Fujifilm Biotechnologies California, a contract development and manufacturing organizati...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/the-fly/briacell-arranges-scalable-manufacturing-with-fujifilm-biotechnologies-thefly-news?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/the-fly/briacell-arranges-scalable-manufacturing-with-fujifilm-biotechnologies-thefly-news?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","EES","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2651450871","title":"BriaCell Arranges Scalable Manufacturing with FUJIFILM Biotechnologies for Bria-IMT™","url":"https://stock-news.laohu8.com/highlight/detail?id=2651450871","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2651450871?lang=en_us&edition=fundamental","pubTime":"2026-07-15 19:30","pubTimestamp":1784115000,"startTime":"0","endTime":"0","summary":"Arrangement with FUJIFILM Biotechnologies California provides manufacturing capacity for the remainder of BriaCell’s pivotal Phase 3 study and commercial scalability potentialBria-IMT is currently bei","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/15/3327609/0/en/BriaCell-Arranges-Scalable-Manufacturing-with-FUJIFILM-Biotechnologies-for-Bria-IMT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["SYNB","EES","BK4139","BK4585","BK4588","BCTX","IBB","CDMO"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2649823079","title":"BriaCell Engages Consulting and Branding Firms to Support Commercial and Market Access Evaluation of Bria-IMT™","url":"https://stock-news.laohu8.com/highlight/detail?id=2649823079","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2649823079?lang=en_us&edition=fundamental","pubTime":"2026-07-07 19:30","pubTimestamp":1783423800,"startTime":"0","endTime":"0","summary":"Charles River Associates (CRA) to evaluate epidemiology, pricing, prescriber dynamics, and market access potential for Bria-IMT in metastatic breast cancer in the USKaleio to support brand strategies ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/07/07/3323056/0/en/BriaCell-Engages-Consulting-and-Branding-Firms-to-Support-Commercial-and-Market-Access-Evaluation-of-Bria-IMT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646360014","title":"BriaCell Subsidiary Highlights Interim Results, Ongoing Losses","url":"https://stock-news.laohu8.com/highlight/detail?id=2646360014","media":"TIPRANKS","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646360014?lang=en_us&edition=fundamental","pubTime":"2026-06-27 04:33","pubTimestamp":1782506036,"startTime":"0","endTime":"0","summary":"The latest update is out from BriaCell Therapeutics ( ($TSE:BCT) ). On June 26, 2026, BriaPro Therapeutics Corp., a subsidiary of BriaCell Therapeu...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-subsidiary-highlights-interim-results-ongoing-losses?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-subsidiary-highlights-interim-results-ongoing-losses?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2646877362","title":"BriaCell Partners with Uneedle for Scalable Microneedle Administration of Bria-IMT™","url":"https://stock-news.laohu8.com/highlight/detail?id=2646877362","media":"GlobeNewswire","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2646877362?lang=en_us&edition=fundamental","pubTime":"2026-06-25 19:30","pubTimestamp":1782387000,"startTime":"0","endTime":"0","summary":"Agreement supports potential commercial readiness for Bria-IMT using Uneedle’s proprietary microneedle technology for intradermal administrationTechnology is currently used in BriaCell’s pivotal Phase","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/25/3317432/0/en/BriaCell-Partners-with-Uneedle-for-Scalable-Microneedle-Administration-of-Bria-IMT.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2642911418","title":"BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY","url":"https://stock-news.laohu8.com/highlight/detail?id=2642911418","media":"Benzinga Earnings","labels":["dataReport","express"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2642911418?lang=en_us&edition=fundamental","pubTime":"2026-06-10 06:08","pubTimestamp":1781042925,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics (NASDAQ:BCTX) reported quarterly losses of $(0.99) per share. This is a 93.96 percent increase over losses of $(16.40) per share from the same period last year.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":["earning"],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.benzinga.com/news/earnings/26/06/53105477/briacell-therapeutics-q3-eps-0-99-up-from-16-40-yoy","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":"BriaCell Therapeutics Q3 EPS $(0.99) Up From $(16.40) YoY","news_tag":"dataReport,express","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640906961","title":"BriaCell Therapeutics Completes Equity Offering to Fund Operations","url":"https://stock-news.laohu8.com/highlight/detail?id=2640906961","media":"TIPRANKS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640906961?lang=en_us&edition=fundamental","pubTime":"2026-06-03 18:48","pubTimestamp":1780483689,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics ( ($TSE:BCT) ) just unveiled an update. On May 31, 2026, BriaCell Therapeutics entered into a placement agency agreement with...","market":"nz","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"tipranks_highlight","url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-completes-equity-offering-to-fund-operations?utm_source=itigerup.com&utm_medium=referral","rn_cache_url":null,"directOrigin":true},"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.tipranks.com/news/company-announcements/briacell-therapeutics-completes-equity-offering-to-fund-operations?utm_source=itigerup.com&utm_medium=referral","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"tipranks_highlight","symbols":["BK4215","BK4585","BCTX","EQR","BK4588","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640256179","title":"BriaCell Therapeutics Closes $4.7 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640256179","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640256179?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:24","pubTimestamp":1780431888,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics Corp  said Tuesday it has closed its best-efforts offering of roughly 1.45 million shares at $3.25 per share, for gross proceeds of about $4.7 million.Net proceeds will be used for working capital, general corporate purposes, as well as the advancement of business goals, the company said.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4139","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640923783","title":"BriaCell Therapeutics Announces Closing of Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640923783","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640923783?lang=en_us&edition=fundamental","pubTime":"2026-06-03 04:05","pubTimestamp":1780430700,"startTime":"0","endTime":"0","summary":"PHILADELPHIA & VANCOUVER, British Columbia, June  02, 2026  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage biot","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/02/3305594/0/en/BriaCell-Therapeutics-Announces-Closing-of-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640959383","title":"BriaCell Presents Positive Clinical Data at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2640959383","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640959383?lang=en_us&edition=fundamental","pubTime":"2026-06-01 19:30","pubTimestamp":1780313400,"startTime":"0","endTime":"0","summary":"Final Bria-IMT Phase 2 data show 55% >1 year and 27% >2-year survival in heavily pre-treated metastatic breast cancer (MBC) patients treated with Bria-IMT regimen selected for Phase 3TWiST analysis, w","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/06/01/3304255/0/en/BriaCell-Presents-Positive-Clinical-Data-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0757428866.USD","MBC","LU1815336091.USD","ADC","BCTX","BK4195","CPI","PFS","BK4211","BK4080","BK4023","BK4086","BL","BK4231"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640293125","title":"BriaCell Therapeutics Prices $4.7 Million Share Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640293125","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640293125?lang=en_us&edition=fundamental","pubTime":"2026-06-01 15:59","pubTimestamp":1780300785,"startTime":"0","endTime":"0","summary":"BriaCell Therapeutics  said Sunday it priced a best-efforts offering of roughly 1.4 million shares at $3.25 each, raising gross proceeds of about $4.7 million.The offering is expected to close on Tuesday.The company said it plans to use the proceeds for working capital, general corporate purposes, and advancing its business objectives.","market":"sg","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2640818479","title":"BriaCell Therapeutics Announces Pricing of Offering","url":"https://stock-news.laohu8.com/highlight/detail?id=2640818479","media":"GlobeNewswire","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2640818479?lang=en_us&edition=fundamental","pubTime":"2026-06-01 07:59","pubTimestamp":1780271940,"startTime":"0","endTime":"0","summary":"PHILADELPHIA and VANCOUVER, British Columbia, May  31, 2026  (GLOBE NEWSWIRE) -- BriaCell Therapeutics Corp. (Nasdaq: BCTX, BCTXL, BCTXZ) (TSX: BCT) (“BriaCell” or the “Company”), a clinical-stage bio","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/31/3303968/0/en/BriaCell-Therapeutics-Announces-Pricing-of-Offering.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BCTX","BK4139"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2638251974","title":"BriaCell Receives Positive Recommendation from Data Safety Monitoring Board (DSMB) for Phase 3 Study in Metastatic Breast Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2638251974","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2638251974?lang=en_us&edition=fundamental","pubTime":"2026-05-26 19:30","pubTimestamp":1779795000,"startTime":"0","endTime":"0","summary":"Independent DSMB has identified no safety concerns, to date, and recommends continuation of BriaCell’s pivotal Phase 3 study of Bria-IMT plus immune check point inhibitorSixth consecutive positive DSM","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/26/3300964/0/en/BriaCell-Receives-Positive-Recommendation-from-Data-Safety-Monitoring-Board-DSMB-for-Phase-3-Study-in-Metastatic-Breast-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","CPI","BCTX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2637631319","title":"BriaCell Presentations Highlight Positive Clinical Data for Bria-IMT™ at ASCO 2026","url":"https://stock-news.laohu8.com/highlight/detail?id=2637631319","media":"GlobeNewswire","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2637631319?lang=en_us&edition=fundamental","pubTime":"2026-05-22 19:30","pubTimestamp":1779449400,"startTime":"0","endTime":"0","summary":"Final Phase 2 Bria-IMT median overall survival (OS) is 16.6 months (with Phase 3 formulation) Positive Quality of Life (QOL) data from the ongoing Phase 3 study in heavily pre-treated metastatic breas","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/22/3300068/0/en/BriaCell-Presentations-Highlight-Positive-Clinical-Data-for-Bria-IMT-at-ASCO-2026.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4211","BK4080","BK4195","BK4124","CPI","CPS","BK4086","DTH","MBC","BK4231","ADC","BCTX","PFS"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635089191","title":"BriaCell Expands Pipeline to Include an Ovarian Cancer Immunotherapy Candidate, Bria-OVA+™","url":"https://stock-news.laohu8.com/highlight/detail?id=2635089191","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635089191?lang=en_us&edition=fundamental","pubTime":"2026-05-15 19:30","pubTimestamp":1778844600,"startTime":"0","endTime":"0","summary":"BriaCell expands push in women’s health, building on Phase 2 success in advanced metastatic breast cancerBria-OVA+, BriaCell’s next generation personalized immunotherapy candidate for ovarian cancer, ","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/15/3295754/0/en/BriaCell-Expands-Pipeline-to-Include-an-Ovarian-Cancer-Immunotherapy-Candidate-Bria-OVA.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","BCTX","ATCC"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2635714106","title":"BriaCell Completes Manufacturing of Clinical Supplies of Bria-PROS+™ for Prostate Cancer","url":"https://stock-news.laohu8.com/highlight/detail?id=2635714106","media":"GlobeNewswire","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2635714106?lang=en_us&edition=fundamental","pubTime":"2026-05-14 19:30","pubTimestamp":1778758200,"startTime":"0","endTime":"0","summary":"Bria-PROS+ is BriaCell’s next generation personalized off-the-shelf immunotherapy for prostate cancerImmune stimulating components of Bria-PROS+ enhance anti-tumor responsesBriaCell has completed manu","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.globenewswire.com/news-release/2026/05/14/3294795/0/en/BriaCell-Completes-Manufacturing-of-Clinical-Supplies-of-Bria-PROS-for-Prostate-Cancer.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["IND","BCTX","BK4139","PROS"],"isVideo":false,"video":null,"gpt_icon":0}],"profile":{"websiteUrl":"http://briacell.com","stockEarnings":[{"period":"1week","weight":-0.0371},{"period":"1month","weight":0.0552},{"period":"3month","weight":0.0967},{"period":"6month","weight":-0.0948},{"period":"1year","weight":-0.5328},{"period":"ytd","weight":-0.4895}],"compareEarnings":[{"period":"1week","weight":-0.0054},{"period":"1month","weight":0.0197},{"period":"3month","weight":0.01},{"period":"6month","weight":0.1181},{"period":"1year","weight":0.181},{"period":"ytd","weight":0.1171}],"compareStock":{"symbol":"SPY","name":"SPDR S&P 500 ETF Trust"},"description":"BriaCell Therapeutics Corp. operates as a Phase 3 biotechnology company transforming cancer care with its novel cellular immunotherapies. It is conducting a pivotal Phase 3 clinical trial in advanced breast cancer with its Bria-IMT in combination with an immune check point inhibitor. It is also developing personalized off-the-shelf treatments for breast cancer, prostate cancer, and other cancers. The company has a collaboration with Incyte Corporation to evaluate combination of the Bria-IMT. BriaCell Therapeutics Corp. is based in West Vancouver, Canada.","yearOnYearQuotes":[{"month":1,"riseRate":0.2,"avgChangeRate":-0.124732},{"month":2,"riseRate":0.2,"avgChangeRate":-0.077389},{"month":3,"riseRate":0.666667,"avgChangeRate":0.07242},{"month":4,"riseRate":0.166667,"avgChangeRate":-0.063453},{"month":5,"riseRate":0,"avgChangeRate":-0.196006},{"month":6,"riseRate":0.5,"avgChangeRate":0.047269},{"month":7,"riseRate":0.5,"avgChangeRate":-0.150485},{"month":8,"riseRate":1,"avgChangeRate":0.123184},{"month":9,"riseRate":0.666667,"avgChangeRate":0.131123},{"month":10,"riseRate":0,"avgChangeRate":-0.140813},{"month":11,"riseRate":0.6,"avgChangeRate":0.110284},{"month":12,"riseRate":0.2,"avgChangeRate":-0.186609}],"exchange":"NASDAQ","name":"BriaCell Therapeutics Corp.","nameEN":"BriaCell Therapeutics Corp."},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.49.0","shortVersion":"4.49.0","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"pagemeta":{"title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","keywords":"BriaCell Therapeutics Corp.,BCTX,BriaCell Therapeutics Corp.股票,BriaCell Therapeutics Corp.股票老虎,BriaCell Therapeutics Corp.股票老虎国际,BriaCell Therapeutics Corp.行情,BriaCell Therapeutics Corp.股票行情,BriaCell Therapeutics Corp.股价,BriaCell Therapeutics Corp.股市,BriaCell Therapeutics Corp.股票价格,BriaCell Therapeutics Corp.股票交易,BriaCell Therapeutics Corp.股票购买,BriaCell Therapeutics Corp.股票实时行情,购买美股,购买港股,港股开户,美股开户,美股交易,港股交易,开通美港股账户,老虎国际行情","social":{"og_title":"BriaCell Therapeutics Corp.(BCTX),Stock Price, Discussion, News, Quote & History - To The Moon - Tiger Brokers Online Investing Community","og_description":"Find the latest BriaCell Therapeutics Corp.(BCTX) stock quote, history, news, and investing ideas from To The Moon - Tiger Brokers Online Investing Community to stay on top of the markets.","og_image":"https://community-static.tradeup.com/news/9b6dafd60190235ae8e2c95f52c583a0"}}}